This study is evaluating the behavioral and psychosocial effects of the routine offer of RGCT to newly diagnosed primary breast cancer patients who meet criteria for being at-risk of having a BRCA1 or BRCA2 gene mutation. The gene discussed is BRCA1; the disease is breast carcinoma.